BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis. 2008;40 Suppl 2:S225-S228. [PMID: 18598993 DOI: 10.1016/s1590-8658(08)60530-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Whatmough S, Snoswell C, Callaghan G, Lucas G, Barras M, Morris C. Infusion reaction incidence after switching all patients to an infliximab biosimilar in an Australian hospital. Pharmacy Practice and Res. [DOI: 10.1002/jppr.1811] [Reference Citation Analysis]
2 Notararigo S, Martín-Pastor M, Viñuela-Roldán JE, Quiroga A, Dominguez-Munoz JE, Barreiro-de Acosta M. Targeted 1H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF. J Mol Med (Berl) 2021;99:1251-64. [PMID: 34021361 DOI: 10.1007/s00109-021-02094-y] [Reference Citation Analysis]
3 Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227 [PMID: 26600980 DOI: 10.4291/wjgp.v6.i4.219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
4 Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Geraci M, Zali MR. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018;6:1074-1081. [PMID: 30228896 DOI: 10.1177/2050640618774637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
5 Lingohr P, Galetin T, Matthaei H, Straub E, Jafari A, Bölke E, Kalff JC, Vestweber KH. Malignant melanoma of the ileo-anal pouch anastomosis after restorative proctocolectomy for ulcerative colitis: report of a case. Eur J Med Res 2013;18:39. [PMID: 24188588 DOI: 10.1186/2047-783X-18-39] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Sorrentino D, Terrosu G, Paviotti A, Geraci M, Avellini C, Zoli G, Fries W, Danese S, Occhipinti P, Croatto T. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab--a pilot study. Dig Dis Sci. 2012;57:1341-1348. [PMID: 22252267 DOI: 10.1007/s10620-011-2025-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
7 Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M, Study POT. The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. MAbs 2019;11:13-25. [PMID: 30395763 DOI: 10.1080/19420862.2018.1532766] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
8 Esteban S, Clemente C, Koziol A, Gonzalo P, Rius C, Martínez F, Linares PM, Chaparro M, Urzainqui A, Andrés V, Seiki M, Gisbert JP, Arroyo AG. Endothelial MT1-MMP targeting limits intussusceptive angiogenesis and colitis via TSP1/nitric oxide axis. EMBO Mol Med 2020;12:e10862. [PMID: 31793743 DOI: 10.15252/emmm.201910862] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
9 Kim MJ, Kim E, Kang B, Choe YH. Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. Yonsei Med J 2021;62:608-14. [PMID: 34164958 DOI: 10.3349/ymj.2021.62.7.608] [Reference Citation Analysis]
10 Buchbender M, Fehlhofer J, Proff P, Möst T, Ries J, Hannig M, Neurath MF, Gund M, Atreya R, Kesting M. Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study. Clin Oral Investig 2021. [PMID: 34383142 DOI: 10.1007/s00784-021-04093-2] [Reference Citation Analysis]
11 Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res 2021;51:358-73. [DOI: 10.1002/jppr.1754] [Reference Citation Analysis]
12 Triantafyllou C, Nikolaou M, Ikonomidis I, Bamias G, Kouretas D, Andreadou I, Tsoumani M, Thymis J, Papaconstantinou I. Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. Diagnostics (Basel) 2021;11:993. [PMID: 34070768 DOI: 10.3390/diagnostics11060993] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Li YX, Li SR, Li JX, Yang XY, Wang HH. Efficacy of infliximab in the management of steroid-refractory or steroid-dependent ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2012; 20(21): 1987-1992 [DOI: 10.11569/wcjd.v20.i21.1987] [Reference Citation Analysis]
15 Rofaiel R, Kohli S, Mura M, Hosseini-Moghaddam SM. A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Rep 2017;2017:bcr-2017-219956. [PMID: 28500116 DOI: 10.1136/bcr-2017-219956] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci 2021;22:2719. [PMID: 33800290 DOI: 10.3390/ijms22052719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2013;10:413-422. [PMID: 23648935 DOI: 10.1038/nrgastro.2013.69] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
18 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Czaja AJ. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Dig Dis Sci 2022. [PMID: 35147819 DOI: 10.1007/s10620-021-07378-4] [Reference Citation Analysis]
21 Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013;2013:581631. [PMID: 23484133 DOI: 10.1155/2013/581631] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
22 Stefanou AJ. Anorectal melanoma. Seminars in Colon and Rectal Surgery 2015;26:91-5. [DOI: 10.1053/j.scrs.2015.01.007] [Reference Citation Analysis]
23 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
24 du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med 2009;13:1451-63. [PMID: 19522843 DOI: 10.1111/j.1582-4934.2009.00826.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 7.5] [Reference Citation Analysis]
25 Zhang C, Shu W, Zhou G, Lin J, Chu F, Wu H, Liu Z. Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease. Mediators Inflamm 2018;2018:3021863. [PMID: 30595666 DOI: 10.1155/2018/3021863] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
26 Swanson KD, Theodorou E, Kokkotou E. Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm. Curr Opin Gastroenterol 2018;34:384-91. [PMID: 30188406 DOI: 10.1097/MOG.0000000000000485] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics 2019;11:E428. [PMID: 31450748 DOI: 10.3390/pharmaceutics11090428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]